Bharat Parenterals Limited (BOM:541096)
1,313.50
-21.65 (-1.62%)
At close: May 26, 2026
Bharat Parenterals Revenue
In the fiscal year ending March 31, 2026, Bharat Parenterals had annual revenue of 3.45B INR with 1.48% growth. Bharat Parenterals had revenue of 996.24M in the quarter ending March 31, 2026, a decrease of -4.19%.
Revenue
3.45B
Revenue Growth
+1.48%
P/S Ratio
2.62
Revenue / Employee
8.79M
Employees
393
Market Cap
9.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 3.45B | 50.49M | 1.48% |
| Mar 31, 2025 | 3.40B | 791.65M | 30.31% |
| Mar 31, 2024 | 2.61B | 419.14M | 19.11% |
| Mar 31, 2023 | 2.19B | 69.72M | 3.28% |
| Mar 31, 2022 | 2.12B | 51.08M | 2.46% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TTK Healthcare | 8.30B |
| Anuh Pharma | 7.72B |
| Sudarshan Pharma Industries | 7.12B |
| Kopran | 6.81B |
| Wanbury | 6.58B |
| Lincoln Pharmaceuticals | 6.52B |
| Fredun Pharmaceuticals | 6.39B |
| Fermenta Biotech | 5.44B |
Bharat Parenterals News
- 6 months ago - Bharat Parenterals’ subsidiary Innoxel Lifesciences clears EU GMP inspection with zero observations - Business Upturn
- 6 months ago - Bharat Parenterals subsidiary Innoxel Lifesciences clears EU GMP inspection with zero observations - Business Upturn